Apiol

Apiol

SCHEMBL497412

C=CCc1cc(OC)c2c(c1OC)OCO2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 1.00
ALOX15 P16050 1/20 1.00
POLB P06746 3/20 0.68
ALDH1A1 P00352 4/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
ALOX5 P09917 2/20 0.38
GABRA1 P14867 1/20 0.38
CNR2 P34972 1/20 0.38
GABRB2 P47870 1/20 0.38
ACHE P22303 1/20 0.38
DHFR P00374 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38
AR P10275 1/20 0.37
PTGS1 P23219 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Apiol SCHEMBL29410305 1.00 CYP3A4 (1.00) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL3931943 0.89 CYP3A4 (0.80) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL26060412 0.81 CYP3A4 (0.68) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL3486950 0.81 POLB (1.00) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL17778495 0.80 CYP3A4 (0.66) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL25367786 0.80 CYP3A4 (0.67) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL25371015 0.80 CYP3A4 (0.67) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL10539412 0.78 CYP3A4 (0.64) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
Dillapiole SCHEMBL310992 0.77 POLB (0.71) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2
SCHEMBL2424490 0.77 POLB (1.00) CYP3A4ALOX15POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 570 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069551-A1 Patch for treating demyelinating diseases UNIV MAINZ JOHANNES GUTENBERG (DE) 2026-03-12 US claimed
US-12514254-B2 Rosa canina rosehip UNIVERSITA′ DEGLI STUDI DI CAGLIARI (IT) 2026-01-06 US claimed
EP-4587027-A1 PATCH FOR TREATING DEMYELINATING DISEASES Johannes Gutenberg-Universität Mainz (DE) 2025-07-23 EP claimed
US-20240324588-A1 ESSENTIAL OIL MICROPARTICLES FOR POWDER COATING APPLICATIONS Genesee Valley Innovations, LLC 2024-10-03 US claimed
WO-2024056642-A1 PATCH FOR TREATING DEMYELINATING DISEASES Johannes Gutenberg-Universität Mainz (DE) 2024-03-21 WO claimed
EP-4338740-A1 A TRANSDERMAL PATCH FOR PROMOTING OR ACCELERATING MYELINATION AND/OR REMYELINATION Johannes Gutenberg-Universität Mainz (DE) 2024-03-20 EP claimed
US-20240041054-A1 ROSA CANINA ROSEHIP UNIVERSITA' DEGLI STUDI DI CAGLIARI (IT) 2024-02-08 US claimed
EP-4294361-A1 ROSEHIP UNIVERSITA' DEGLI STUDI DI CAGLIARI (IT) 2023-12-27 EP claimed
CN-110658283-B Method for detecting volatile components of folium artemisiae argyi 天津中医药大学 2022-11-01 CN claimed
WO-2022191398-A1 METHOD FOR PREPARING INSECTICIDE MASTERBATCH FOR NON-WOVEN FABRIC, INSECTICIDE MASTERBATCH FOR NON-WOVEN FABRIC, NON-WOVEN FABRIC, AND ARTICLE 도레이첨단소재 주식회사 2022-09-15 WO claimed
WO-2011092602-A2 METHODS OF CONTROLLING THE BREEDING BEHAVIOR OF BUTTERFLIES UNIVERSITY OF THE WEST INDIES, A REGIONAL INSTITUTION, ESTABLISHED BY ROYAL CHARTER (JM) 2011-08-04 WO claimed
EP-1767514-B1 Process for the isomerisation of alkenylalkoxybenzenen SYMRISE GMBH & CO KG (DE) 2010-03-31 EP claimed
EP-1793796-B1 USE OF AROMA SUBSTANCE MIXTURES AS AGENTS AGAINST BAD BREATH SYMRISE GMBH & CO KG (DE) 2009-12-09 EP claimed
CN-101541318-A Method for improving bioavailability of renin inhibitor NOVARTIS AG (CH) 2009-09-23 CN claimed
CN-100448924-C Preparation for fly-repellent plastic-bottle cap and use in seasoning package product thereof UNIV HUANAN AGRICULTURE (CN) 2009-01-07 CN claimed
CN-101186772-A Helminthic emulsion paint and preparation method thereof UNIV SOUTH CHINA AGRICULT (CN) 2008-05-28 CN claimed
EP-1767514-A1 Process for the isomerisation of alkenylalkoxybenzenen Symrise GmbH & Co. KG (DE) 2007-03-28 EP claimed
CN-1709957-A Preparation for fly-repellent plastic-bottle cap and use in seasoning package product thereof UNIV HUANAN AGRICULTURE (CN) 2005-12-21 CN claimed
EP-1523896-A1 Composition for oral ingestion Cognis Iberia, S.L. (ES) 2005-04-20 EP claimed
US-5720304-A DIAGNOSIS BY CONVENTIONAL MEDICAL TECHNIQUE OR BI-DIGITAL-O-RING TEST; HAVING PATIENT INGEST ANTIBIOTIC OR ANTIVIRAL AGENT, ALSO INGEST A HERB CONCENTRATION OF UMBELLIFERAE FAMILY OVER SUSTAINED PERIOD OF TIME OMURA YOSHIAKI (US) 1998-02-24 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260069551-A1 Patch for treating demyelinating diseases PMP22, PLP2, MYT1 CYP3A4 4770/4885ALOX15 4181/4885POLB 491/4885
US-20240324588-A1 ESSENTIAL OIL MICROPARTICLES FOR POWDER COATING APPLICATIONS EXOSC9, EXOSC4, PHOSPHO1 CYP3A4 4286/4885ALOX15 41/4885POLB 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.